Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease.

Crohn's disease (CD) and ulcerative colitis (UC) are two types of inflammatory bowel diseases (IBD) diagnosed by chronic inflammation of the gastrointestinal system. Despite being the gold standard for assessing the therapeutic response to biological…

Preview only. Read the full abstract at the source